Trial Profile
A Phase IIa Study of RItuximab and VArlilumab in Relapsed or Refractory B-cell Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Varlilumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms RiVa
- 11 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 04 Sep 2023 Planned End Date changed from 31 Jan 2023 to 31 Dec 2023.
- 04 Sep 2023 According to ISRCTN: Current Controlled Trials record, recruitment end date was found to be 31 Dec 2020